Search Results

Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis

Authors: Turza, Kristin; Dengel, Lynn T.; Harris, Rebecca C.; Patterson, James W.; White, Kevin; Grosh, William W.; Slingluff, Craig L.

Source: Journal of Cutaneous Pathology, Volume 37, Number 1, January 2010 , pp. 94-98(5)

Publisher: Blackwell Publishing

Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma

Authors: Sriprakash, Kavita; Godbolt, Amanda

Source: Australasian Journal of Dermatology, Volume 50, Number 3, August 2009 , pp. 211-213(3)

Publisher: Blackwell Publishing

Topical Imiquimod: A Review of its Use in the Management of Anogenital Warts, Actinic Keratoses, Basal Cell Carcinoma and Other Skin Lesions

Authors: Wagstaff, Antona J.; Perry, Caroline M.

Source: Drugs, Volume 67, Number 15, 2007 , pp. 2187-2210(24)

Publisher: Adis International

Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study

Authors: Nogueira, Sandra A. F.; Torres, Sheila M. F.; Malone, Erin D.; Diaz, Sandra F.; Jessen, Carl; Gilbert, Sophie

Source: Veterinary Dermatology, Volume 17, Number 4, August 2006 , pp. 259-265(7)

Publisher: Blackwell Publishing

First case series on the use of imiquimod for morphoea

Authors: Dytoc, M.; Ting, P.T.; Man, J.; Sawyer, D.; Fiorillo, L.

Source: British Journal of Dermatology, Volume 153, Number 4, October 2005 , pp. 815-820(6)

Publisher: Blackwell Publishing

The imidazoquinolines — mechanism of action and therapeutic potential in HPV-associated disease

Author: Stanley, Margaret A.

Source: Papillomavirus Report, Volume 16, Number 3, May 2005 , pp. 141-146(6)

Publisher: Maney Publishing

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe

Authors: Schulze, H.J.; Cribier, B.; Requena, L.; Reifenberger, J.; Ferrándiz, C.; Garcia Diez, A.; Tebbs, V.; McRae, S.

Source: British Journal of Dermatology, Volume 152, Number 5, May 2005 , pp. 939-947(9)

Publisher: Blackwell Publishing

Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod

Authors: Wenzel, Joerg; Uerlich, Manfred; Haller, Otto; Bieber, Thomas; Tueting, Thomas

Source: Journal of Cutaneous Pathology, Volume 32, Number 4, April 2005 , pp. 257-262(6)

Publisher: Blackwell Publishing

Cellular reactions of malignant, semimalignant and premalignant conditions of the skin under immunostimulating therapy with imiquimod

Authors: Sommer, A.; Stücker, M.; Oster-Schmidt, C.; Altmeyer, P.; Bacharach-Buhles, M.

Source: Journal of Investigative Dermatology, Volume 123, Number 5, November 2004 , pp. A87-A97(1)

Publisher: Blackwell Publishing

Use of Imiquimod Cream 5% in the Treatment of Localized Morphea

Authors: Man, Jeremy; Dytoc, Marlene

Source: Journal of Cutaneous Medicine and Surgery, Volume 8, Number 3, June 2004 , pp. 166-169(4)

Publisher: Springer

Imiquimod as a dermatological therapy

Authors: Tran H.; Moreno G.; Shumack S.

Source: Expert Opinion on Pharmacotherapy, Volume 5, Number 2, 1 February 2004 , pp. 427-438(12)

Publisher: Informa Healthcare

Immunotherapy of Basal Cell Carcinoma: Evolving Approaches

Authors: Gaspari A.A.; Sauder D.N.

Source: Dermatologic Surgery, Volume 29, Number 10, October 2003 , pp. 1027-1034(8)

Publisher: Blackwell Publishing

New Approaches to the Treatment of Actinic Keratosis

Authors: Jeffes III E.W.B.; Chen J.T.

Source: American Journal of Cancer, Volume 2, Number 3, 2003 , pp. 151-168(18)

Publisher: Adis International

Lip Silicone Granulomatous Foreign Body Reaction Treated With Aldara (Imiquimod 5%)

Authors: Baumann L.S.; Halem M.L.

Source: Dermatologic Surgery, Volume 29, Number 4, April 2003 , pp. 429-432(4)

Publisher: Blackwell Publishing

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

Author: Stanley, M. A.

Source: Clinical & Experimental Dermatology, Volume 27, Number 7, October 2002 , pp. 571-577(7)

Publisher: Blackwell Publishing

Imiquimod 5% cream is an acceptable treatment option for external anogenital warts in uncircumcised males

Authors: Maw, RD; Kinghorn, GR; Bowman, CA; Goh, BT; Nayagam, AT; Nathan, M

Source: Journal of the European Academy of Dermatology & Venereology, Volume 16, Number 1, January 2002 , pp. 58-62(5)

Publisher: Blackwell Publishing

Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry

Authors: Gutzmer R.; Kaspari M.; Vogelbruch M.; Kiehl P.; Kapp A.; Werfel T.; Brodersen J-P.

Source: British Journal of Dermatology, Volume 147, Number 1, July 2002 , pp. 160-165(6)

Publisher: Blackwell Publishing

Immunomodulation as a treatment strategy for genital herpes: review of the evidence

Authors: Miller R.L.; Tomai M.A.; Harrison C.J.; Bernstein D.I.

Source: International Immunopharmacology, Volume 2, Number 4, March 2002 , pp. 443-451(9)

Publisher: Elsevier

The Immune Response Modifier Resiquimod Mimics CD40-Induced B Cell Activation

Authors: Bishop G.A.; Ramirez L.M.; Baccam M.; Busch L.K.; Pederson L.K.; Tomai M.A.

Source: Cellular Immunology, Volume 208, Number 1, 25 February 2001 , pp. 9-17(9)

Publisher: Elsevier

Emerging therapies for human papillomavirus infection

Author: Wilson F.X.

Source: Expert Opinion on Emerging Drugs, Volume 6, Number 2, 1 October 2001 , pp. 199-207(9)

Publisher: Informa Healthcare